Absci, PrecisionLife collaborate to develop novel biotherapeutics for chronic diseases

Absci, PrecisionLife collaborate to develop novel biotherapeutics for chronic diseases

Absci (Nasdaq: ABSI), a generative AI drug creation company, and PrecisionLife, a leader in computational biology, today announced a significant collaboration. This partnership is set to develop a portfolio of potential therapeutics, targeting unmet medical needs in chronic diseases. The collaboration leverages Absci’s prowess in antibody design and PrecisionLife’s expertise in complex disease biology, aiming […]

Absci collaborates with AstraZeneca for AI-designed oncology antibody

Absci collaborates with AstraZeneca for AI-designed oncology antibody

Absci Corporation (Nasdaq: ABSI), a leader in generative AI antibody discovery, announced a groundbreaking collaboration with AstraZeneca, a global biopharmaceutical company. This partnership aims to develop an AI-designed antibody targeting oncology, potentially accelerating the discovery of a new cancer treatment candidate. Financial Commitment and Collaboration Details The agreement encompasses an upfront commitment, along with R&D […]